WuXi Biologics and Medigene Enter into a Research Collaboration for Off-the-Shelf TCR-Guided T Cell Engagers
- Written by PR Newswire
- Partnership leverages Medigene's leadership for T cell receptor (TCR) generation and characterization and WuXi Biologics' unique anti-CD3 mAb, its T cell engager (TCE) platform and proprietary bispecific antibody platform WuXiBody™
- Collaboration is a three-year and potentially multi-TCR program partnership
SHANGHAI and MUNICH, Aug. 8, 2024 /PRN...













